Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Episode 383

0:00-19:13

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the vaccine’s prospects and the broader implications. The analysts also discuss Roche/Genentech’s deal with Hanmi, which will add to the MNC’s obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that has revived questions of the agency's independence. View full story: https://www.biocentury.com/article/660596 #CancerVaccines #Obesity #FDA #Oncology #DrugDevelopment 00:00 - Introduction 03:03 - Moderna 11:12 - Genentech obesity deal 15:08 - Trump's FDA pick To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Publisher

BioCentury This Week

Published

August 25, 2026

Duration

19 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BioCentury

BT

BioCentury This Week

@biocenturythisweek

#moderna #genentechobesitydeal #trumpsfdapick #lifesciences

The Nile